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Abstract: The objective of this study was to assess the safety and
efficacy of the fixed combination calcipotriene 0.005% plus betametha-
sone dipropionate 0.064% topical suspension in adolescents with exten-
sive scalp psoriasis. In this phase II, open-label, 8-week study,
adolescents with psoriasis (ages 12–17 years) with 20% or more of the
scalp area affected (at least moderate severity according to Investigator’s
Global Assessment [IGA]) were assigned to once-daily treatment with
calcipotriene plus betamethasone dipropionate topical suspension. The
primary endpoint was safety, focusing on calcium metabolism and
hypothalamic–pituitary–adrenal axis function. Secondary efficacy end-
points were the proportion of patient’s achieving treatment success (clear
or almost clear disease according to the IGA and clear or verymild disease
according to the Patient’s Global Assessment [PaGA]) and percentage
change in investigator-assessed Total Sign Score (TSS). Pruritus was also
assessed. Overall, 31 patients received treatment. Sixteen patients (52%)
experienced a total of 20 adverse events; 19 were considered unrelated to
study treatment, 14 were mild, and none were serious or lesional or
perilesional on the scalp. One patient showed signs of mild adrenal
suppression at week 4; the patient discontinued treatment and had normal
test results at follow-up 4 weeks later. No cases of hypercalcemia were
reported. By treatment end, treatment success was reported for 17
patients (55%) according to the IGA and 18 (58%) according to the PGA.
Mean TSS improved from 6.9 at baseline to 2.9 at treatment end (59%
improvement). By week 8, 28 patients (90%) experienced mild or no
itching, versus 20 (65%) at baseline. Once-daily calcipotriene
plus betamethasone dipropionate topical suspension was well tolerated
and efficacious for the treatment of scalp psoriasis in adolescents.
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Psoriasis is a common chronic inflammatory skin
disease that is associated with serious comorbidities
such as cardiovascular disease, depression, and pso-
riatic arthritis (1,2). Approximately 35% of patients
with psoriasis develop the disease before the age of 20
years and 25% are diagnosed between 10 and 19 years
of age (3). In this adolescent age group, psoriasis can
have a particularly significant impact on quality of
life, including social interactions (4). In particular,
scalp lesions are a common manifestation in younger
individuals with psoriasis vulgaris (5) and may repre-
sent a serious concern to patients because of the
visibility of lesions and scaling, accompanied by
feelings of stigmatization.
Current guidelines for the first-line treatment of
mild to moderate psoriasis recommend the topical
use of vitamin D analogues and corticosteroids (6).
Safety concerns typically associated with these mono
therapies include skin irritation and hypercalcemia
for vitamin D analogues, and skin atrophy, adrenal
suppression, and stunted growth with long-term use
for corticosteroids. A fixed-combination topical
preparation containing the vitamin D analogue
calcipotriene and the corticosteroid betamethasone
dipropionate has been developed and is well toler-
ated, with superior efficacy than the individual
components for treatment of adult psoriasis vulgaris
(7–9). Therapeutic benefit is achieved with the fixed
combination, promoting greater anti-inflammatory
and antiproliferative effects than for either active
ingredient alone, coupled with a faster response and
potentially fewer safety concerns (10,11) than with
monotherapies.
The choice of topical treatment vehicle influences
patient adherence and is a key factor that impacts
upon effectiveness. Certain formulations, such as
ointments, are often perceived as being messy, with
time-consuming application that can deter patients
from adhering to their treatment regimens (12,13).
Adherence to skin disease treatments is particularly
poor in adolescents, who often choose not to use
medications as the result of social pressures and
inconvenience (14). A fixed-combination lipophilic,
alcohol-free topical suspension formulation may offer
a beneficial treatment option for adolescents, provid-
ing cosmetic acceptability, convenience, and ease of
use, but no specific clinical investigation of this fixed-
combination formulation has previously been per-
formed in an adolescent population.
This trial investigated the safety, with particular
focus on calcium metabolism, as well as hypotha-
lamic–pituitary–adrenal (HPA) axis function through
dynamic testing, and efficacy of once-daily use of
calcipotriene 0.005% plus betamethasone dipropio-
nate (0.064%) topical suspension in adolescents with
extensive psoriasis vulgaris of the scalp.
MATERIALS AND METHODS
Patients
Eligible patients were ages 12–17 years and had a
clinical diagnosis of scalp psoriasis vulgaris amenable
to topical treatment (up to a maximum of 60 g of
study medication per week). All patients had clinical
signs or prior diagnosis of psoriasis vulgaris of the
trunk or limbs as assessed during screening (see Study
Design). At inclusion, psoriasis of the scalp had to
involve 20% or more of the scalp area and be of at
least moderate severity according to the Investigator’s
Global Assessment (IGA). Patients also had to have
albumin-corrected serum calcium levels below the
upper reference limit and normal HPA axis function
before treatment (serum cortisol concentration >5 lg/
dL before adrenocorticotropic hormone [ACTH]
challenge and >18 lg/dL 30 minutes after ACTH
challenge).
Themain exclusion criteria were a history of serious
allergy, allergic asthma, or serious allergic skin rash
and known or suspected hypersensitivity to any
medication, including synthetic ACTH (cosyntropin)
or to any component of the calcipotriene plus
betamethasone dipropionate topical suspension.
Patients were also excluded if they had received topical
or systemic treatment with corticosteroidswithin 2 and
12 weeks, respectively, before baseline. Patients were
excluded if they had been treated with adalimumab,
alefacept, or infliximab within 2 months before base-
line; with etanercept within 4 weeks before baseline; or
with ustekinumab within 4 months before baseline.
Patients who were treated within 4 weeks before
baseline with medications that might affect the HPA
axis function test (e.g., estrogen, enzymatic inducers or
inhibitors, antidepressants) or calcium metabolism
assessments (e.g., calcium or vitamin D supplements,
diuretics, antiepileptics) were also excluded. For other
systemic therapies (e.g., retinoids, immunosuppres-
sants, psoralen plus ultraviolet [UVA]), patients were
excluded if they had been treated within 4 weeks
before baseline. Other exclusion criteria includedUVB
therapy within the 2 weeks before baseline, diabetes
mellitus, current diagnosis of unstable forms of pso-
riasis, skin infection, infestations or atrophy of the
scalp, and severe renal or hepatic disorders.
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Study Design
This was a phase II, multicenter, open-label, single-
arm, 8-week study in the United States. The trial
consisted of three phases: a washout or screening
period, a treatment period, and a follow-up period
(Fig. 1). Patients entered a washout period (up to
8 weeks) if they had been treated with antipsoriatic
therapies or other relevant medication according to
the exclusion criteria. Patients were then assigned to
once-daily treatment with calcipotriene plus beta-
methasone dipropionate topical suspension (Taclonex
topical suspension, Daivobet gel, or Dovobet gel;
LEO Pharma A/S, Ballerup, Denmark) for up to
8 weeks. Patients were permitted to use other topical
antipsoriatic treatments concomitantly, except for
corticosteroids, on the trunk, limbs, and face, but no
other scalp products were allowed during the treat-
ment period. Patients whose scalp psoriasis cleared
after 4 weeks of treatment were required to leave the
trial (in accordance with the U.S. label instructions at
the time, i.e., apply to the affected scalp areas for 2
weeks or until cleared; treatment may be continued
for up to 8 weeks); patients who had signs of scalp
psoriasis after 4 weeks continued treatment for up to
a further 4 weeks. If the scalp psoriasis cleared at
week 2 or 6, patients stopped treatment but remained
in the trial; treatment was to be reinitiated if scalp
psoriasis reappeared. The trial was conducted in
accordance with the principles of the Declaration of
Helsinki and good clinical practice and institutional
review boards approved the protocol. The parents or
legal guardians of the patients provided written
informed consent for their participation in the trial.
Study Objectives
The primary objective was to evaluate the safety (with
particular focus on the effect on calcium metabolism,
as well as HPA axis function through dynamic testing)
of once-daily use of calcipotriene plus betamethasone
dipropionate topical suspension in adolescents (ages
Figure 1. Study design excl, exclusion; FU, follow-up; incl, inclusion; SV, screening visit..
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12–17 years) with scalp psoriasis. The secondary
objective was to evaluate the investigator- and
patient-assessed efficacy of the once-daily treatment
regimen in this population.
Assessments
Adverse events (AEs) and efficacy were assessed at
baseline (screening visit [SV2] and day 0) and at weeks
2 (day 14), 4 (day 28), 6 (day 48), and 8 (day 56). HPA
axis function was assessed using a rapid standard-dose
cosyntropin test (ACTH challenge test) at baseline
(SV2) and weeks 4 and 8. Briefly, 2.5 mL of venous
blood was drawn before an intravenous bolus injec-
tion of 250 lg of cosyntropin was administered; two
additional 2.5-mL samples of venous blood were
drawn 30 and 60 minutes after the injection. The
primary response criterion for HPA axis evaluation
was a serum cortisol level of 18 lg/dL or less at
30 minutes or at both 30 and 60 minutes after ACTH
challenge, which would indicate possible adrenal
suppression. Blood samples were collected at baseline
(SV2) and weeks 4 and 8 before the ACTH challenge
test for clinical laboratory tests including markers of
calcium metabolism (calcium, phosphate, and para-
thyroid hormone), other biochemistry, and hematol-
ogy. Before the visits at baseline (SV2) and weeks 4
and 8, a 24-hour urinary sample was collected for
assessment of total excretion and creatinine-corrected
ratios of calcium, phosphate, sodium, and hydroxy-
proline. Three days before and during urine collection,
consumption of calcium-rich nutrients was to be kept
constant and the daily number of “calcium servings”
(corresponding to approximately 300 mg of calcium)
was to be limited to five. The primary response criteria
for calcium metabolism were changes from baseline in
albumin-corrected serum calcium, 24-hour urinary
calcium excretion, and urinary calcium:creatinine
ratio. Patients with an ongoing AE possibly or
probably related to study medication or those with
an albumin-corrected serum calcium value above the
reference range attended a follow-up visit 14 days
after the end of treatment. A second follow-up at
4 weeks after treatment was required for patients with
a serum cortisol value of 18 lg/dL or less 30 minutes
after the ACTH challenge test.
Investigators evaluated the severity of scalp psori-
asis using the six-point IGA scale (clear, almost clear,
mild, moderate, severe, very severe); treatment success
was defined as an assessment of clear or almost clear.
Clinical signs of redness, thickness, and scaliness of
the scalp psoriasis plaques were assessed using a
numerical scale (0 = none, 1 = mild, 2 = moderate,
3 = severe, 4 = very severe); the sum of the three
scores constituted the Total Sign Score (TSS). TSS
success was defined as a total score of 1 or less. Patient
assessment of disease severity was evaluated using the
five-point Patient’s Global Assessment (PaGA) scale
(clear, very mild, mild, moderate, severe); treatment
success was defined as an assessment of clear or very
mild. Patients also assessed the degree of pruritus of
the scalp (none, mild, moderate, severe). Adherence to
treatment was evaluated at visits from week 2 to 8 by
asking each patient whether they used the medication
as prescribed and recording the number of applications
missed. The bottles dispensed were returned at each
visit and weighed to calculate the amount of drug used.
Statistical Analysis
A sample size of 30 patients evaluable for HPA axis
function was deemed adequate for this trial. No
formal statistical analyses were performed and data
are presented descriptively (with two-sided 95%
confidence intervals for primary and secondary end-
points involving laboratory measurements and effi-
cacy assessments). All patients who received study
medication were included in the full analysis set. All
patients who applied study medication and for whom
the presence or confirmed absence of AEs was
available were included in the safety analysis set.
For analysis of HPA axis function (by means of the
ACTH challenge test), a per-protocol analysis set was
defined by exclusion of the following patients from the
full analysis set: those who did not use the study
medication, did not have normal HPA axis function at
baseline, or did not have data from the ACTH
challenge tests on treatment.
Baseline was defined as the last assessment per-
formed before application of treatment. The end-of-
treatment value was defined as the last value recorded
for that parameter up to and including week 8.
Efficacy data and laboratory data were analyzed
according to visit using an observed cases approach
(involving only subjects who attended each specific
visit), except for the tabulation of end-of-treatment
values, for which the last observation carried forward
approach was used.
RESULTS
Patients
Between April 2010 and August 2012, 45 patients
were enrolled and attended the initial screening
assessment, and 31 patients received treatment
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(Fig. 1) and were included in the full and safety
analyses sets. The median age of the patients was
15.0 years (range 12–17 yrs), 12 patients (39%) were
male (safety analysis set; Table 1), and for 19
patients (61%), the age of onset of scalp psoriasis
was 10 to 14 years (<10 yrs for 10 patients [32%]
and >14 yrs for 2 patients [7%]). At baseline,
patients’ TSS ranged from 4 to 11. Patients’ mean
body mass index (BMI) was 26.8 kg/m² and 16
patients (52%) had a BMI outside the normal range
(normal range 18.5–24.9 kg/m²), and most were
above the upper limit of this range. Seventeen
patients (55%) treated with calcipotriene plus
betamethasone dipropionate topical suspension were
fully adherent to treatment, and only five (16%)
missed more than 10% of applications. The mean
weekly use of the topical suspension over the entire
treatment period was 24.5 g (range 0.7–59.9 g).
Safety and Tolerability
Sixteen patients (52%) experienced a total of 20 AEs;
14 were mild in severity and none were serious or
lesional/perilesional on the scalp. The most common
AEs were cough (n = 3; 10%), oropharyngeal pain
(n = 3; 10%), nasopharyngitis (n = 2; 7%), and upper
respiratory tract infection (n = 2; 7%). The investiga-
tor considered only one AE to be possibly related to
study treatment—a patient with laboratory signs of
adrenal suppression at week 4 (serum cortisol con-
centration 16.8 lg/dL at 30 minutes after ACTH
challenge; Fig. 2). This adverse drug reaction was
judged to be mild. The patient discontinued
treatment, and a normal ACTH challenge test was
reported at the follow-up visit 4 weeks after the end of
study treatment. No other patients showed signs of
adrenal suppression.
Overall, mean changes from baseline in albumin-
corrected serum calcium (reference range 8.4–
10.3 mg/dL [2.1–2.6 mM]), 24-hour urinary calcium
excretion (reference range 100–300 mg/24 h [2.5–
7.5 mmol/24 h]), and urinary calcium:creatinine ratio
(reference range 0.01–0.33 mg/g [0.2–8.2 mmol/g])
were not considered to be clinically relevant. The
mean albumin-corrected serum calcium level was
9.04 mg/dL (2.26 mM) at baseline, with mean changes
of –0.112 mg/dL (–0.028 mM) at week 4, 0.008 mg/dL
(0.002 mM) at week 8, and –0.028 mg/dL (–0.007 mM)
at the end of treatment. None of the patients had
albumin-corrected serum calcium levels above the
laboratory upper reference limit at these time points.
At baseline the mean 24-hour urinary calcium excre-
tion value was 121.2 mg/24 h (3.03 mmol/24 h), with
mean changes of 8.00 mg/24 h (0.20 mmol/24 h) at
week 4, 2.40 mg/24 h (0.06 mmol/24 h) at week 8,
and 4.80 mg/24 h (0.12 mmol/24 h) at the end of
treatment. The mean urinary calcium:creatinine ratio
was 0.13 mg/g (3.20 mmol/g) at baseline, with mean
changes of 0.007 mg/g (0.179 mmol/g) at week 4,
less than –0.001 mg/g (<0.005 mmol/g) at week 8,
and 0.004 mg/g (0.096 mmol/g) at the end of treat-
ment. No patients had clinically relevant changes in
TABLE 1. Demographic and Baseline Characteristics
Characteristic Safety analysis set (n = 31) Per-protocol analysis set (n = 30)
Age, years, median (range) 15.0 (12–17) 15.0 (12–17)
Male, n (%) 12 (39) 11 (37)
Race, n (%)
White 28 (90) 27 (90)
Black or African American 1 (3) 1 (3)
Asian 1 (3) 1 (3)
Other 1 (3) 1 (3)
Body mass index, kg/m², mean (range) 26.8 (15.7–47.1) 27.1 (15.7–47.1)
Duration of scalp psoriasis, years, mean (range) 4.7 (1–11) 4.8 (1–11)
Investigator-assessed extent of psoriasis, %, mean (range)
Total body surface area 5.2 (1–13) 5.2 (1–13)
Scalp 60.4 (20–100) 61.1 (20–100)
Investigator’s Global Assessment, n (%)
Moderate 21 (68) 20 (67)
Severe 8 (26) 8 (27)
Very severe 2 (7) 2 (7)
Patient’s Global Assessment, n (%)
Very mild 3 (10) 2 (7)
Mild 5 (16) 5 (17)
Moderate 18 (58) 18 (60)
Severe 5 (16) 5 (17)
The per-protocol analysis set comprised 30 patients; one patient was excluded who did not meet the inclusion criterion of normal hypothalamic–
pituitary–adrenal axis function at baseline.
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24-hour urinary calcium excretion or urinary calcium:
creatinine ratio. There were no clinically relevant
changes in other markers of calcium metabolism or in
any other biochemistry or hematology parameters.
Efficacy
Treatment success according to IGA was reported in
17 patients (55%) by the end of treatment (Fig. 3),
including three patients who achieved clear disease
status at week 4 and completed the study at this time
point according to the protocol. The mean TSS
improved from 6.9 at baseline to 2.9 at the end of
treatment (59% improvement). The proportion of
patients with TSS success was 39% (n = 12) at the end
of treatment, compared with 0% at baseline. Changes
in disease severity as evaluated by patients (PaGA)
demonstrated similar results to the investigator
assessments, with the number of patients reporting
treatment success increasing from 3 (10%) at baseline
to 18 (58%) at the end of treatment. Already by week
2, 45% of the patients achieved treatment success
according to the PaGA, and 32% were assessed as
showing treatment success according to the IGA.
Patients also reported itch relief, with 28 (90%)
experiencing mild or no itching at the end of treatment
compared with 20 (65%) at baseline (Fig. 4).
DISCUSSION
This study assessed the safety and efficacy of
calcipotriene plus betamethasone dipropionate topi-
cal suspension in adolescents with moderate to very
severe scalp psoriasis. The topical treatment was well
tolerated and efficacious in these patients with exten-
sive scalp psoriasis (mean coverage 60.4% of the scalp
area).
Our safety findings are comparable with those of
adult studies of once-daily administration of calcipo-
triene plus betamethasone dipropionate topical sus-
pension (8,15). No adolescents experienced lesional or
perilesional events on the scalp in this study, whereas
in adult studies, 3% to 6% of patients typically report
such events (16–18). In the current study, reversible
adrenal suppression was observed in one patient at
4 weeks, although this was without clinical manifes-
tation. This patient used 94 g of product during the
first 2 weeks of the study period, compared with an
average 51 g in the study population. In adults, two
patients (5%) showed laboratory signs of adrenal
suppression after 4 weeks of treatment of extensive
body and scalp psoriasis with calcipotriene plus
betamethasone dipropionate topical suspension, but
normal serum cortisol response was documented in
these patients at a follow-up visit 4 weeks later (15).
A recent systematic review showed that reversible
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Figure 2. Serum cortisol concentration 30 minutes after
adrenocorticotropic hormone challenge at weeks 4 and 8
according to the average weekly amount of study drug
used during the first 4 and 8 weeks. The single patient
(patient 1016) with a cortisol concentration below the
defined cutoff level for a normal response is indicated in
the figure.
Figure 3. Proportion of patients experiencing treatment
success as determined according to Investigator’s Global
Assessment (IGA) and Patient’s Global Assessment
(PaGA) and 95% confidence intervals. Treatment success
was defined as an assessment of clear or almost clear for
the IGA or clear or very mild for the PaGA. Week 8 data
include only observed cases at that time point and end-of-
treatment data include the last value recorded for that
parameter.
Figure 4. Patient assessment of itching. Week 8 data
include only observed cases at that time point and end-of-
treatment data include the last value recorded for that
parameter.
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adrenal suppression with clinical manifestations was
rarely reported in adults, compared with the large
numbers of patients using topical steroid treatments
for psoriasis worldwide, but laboratory signs of
transient reduction of HPA axis function were
frequent (19). Instances of adrenal suppression in
short-term psoriasis studies were usually seen early on
in treatment, with cortisol levels returning to normal
within weeks, which is probably analogous to resto-
ration of the epidermal barrier helping to lower
steroid absorption with healing (19). High doses of
topical vitamin D analogues, such as calcipotriene,
have been associated with hypercalcemia (20) result-
ing from interaction between the vitamin D receptor
and genes regulating calcium metabolism. In line with
previous studies of calcipotriene plus betamethasone
dipropionate topical suspension, no cases of hyper-
calcemia or clinically relevant increases in urinary
calcium or other parameters of calcium metabolism
were observed (9,15,16).
A treatment success rate (according to the IGA) of
55% was achieved in this study. In adult studies in
scalp psoriasis, 68% to 72% of patients achieved
treatment success according to the IGA at week 8,
although eligibility criteria tended to include all
disease severities and ≥ 10% total scalp involvement
(16–18). The 58% treatment success according to the
PaGA achieved here compares with 69% to 83% in
8-week studies in adults (16–18). Treatment success
was already demonstrated by week 2, at which point
45% of patients reported treatment success (PaGA)
and 32% were assessed as showing treatment success
by the investigator (IGA). The evidence of early
efficacy of the fixed-combination topical suspension in
adolescents is consistent with findings in adult studies
(16–18).
Clinically relevant relief of pruritus, as assessed by
patients, was also observed in this study, with 90%
reporting mild or no itching by the end of treatment,
compared with 65% at baseline. Pruritus is a common
distressing aspect of psoriasis (21), and it may be
particularly disturbing on the scalp (22). It can cause
pronounced discomfort, often associated with a loss
of sleep, and can negatively affect daily activities, such
as the ability to attend school or work and a reduction
in productivity (23). Alleviation of pruritus can
therefore afford significant improvement to a patient’s
quality of life and is an important feature of symptom
relief with the calcipotriene plus betamethasone
dipropionate topical suspension that goes beyond
the direct objective of improving skin lesions.
Data concerning topical psoriasis treatments in
adolescent patients are limited. Only four reported
pediatric studies have investigated topical psoriasis
products for a minimum duration of 8 weeks (24–27).
Calcipotriene ointment was well tolerated and effec-
tive in two 8-week studies in children ages 2 to 14
years and one 12- to 106-week study in 8- to 15-year-
olds, although the latter included only 12 patients
(24–26). Calcipotriene ointment was reported to be of
benefit over 8 weeks in four adolescent patients (ages
13–17 years) (27). In the current study we assessed
efficacy and safety after treatment with calcipotriene
plus betamethasone dipropionate topical suspension
specifically in adolescents spanning the full age range
of 12 to 17 years. Previous studies have included
adolescents within the wider setting of childhood, not
addressing this specific age group.
In conclusion, the results of this study indicate that
calcipotriene plus betamethasone dipropionate topical
suspension is a well tolerated and efficacious once-daily
treatment regimen for scalp psoriasis in adolescents.
This is one of two studies (the other being conducted in
Europe and Canada) evaluating the safety and efficacy
of this topical suspension in adolescents with moderate
to very severe scalp psoriasis.
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